• Explore /
  • Poster
  • / BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.

BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.

Abstract Poster

Authors

null

Jennifer L. Spratlin

Alberta Health Services, Edmonton, AB, Canada

Jennifer L. Spratlin , Grainne O´Kane , Rachel Anne Goodwin , Elaine McWhirter , Darby Thompson , Khalif Halani , Michelle Jones , Malcolm Snow , Edward Russell McAllister , Andres Machado , Yasmin Lemmerick , Jim Pankovich

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT04421820

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3031)

DOI

10.1200/JCO.2022.40.16_suppl.3031

Abstract #

3031

Poster Bd #

23

Abstract Disclosures

Similar Posters

First Author: Grainne M. O'Kane

First Author: Grainne M. O'Kane

First Author: Do-Youn Oh

First Author: Jeffrey R. Infante